Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population.

Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population. Leuk Lymphoma. 2021 08; 62(8):1869-1876.

View in: PubMed

subject areas

Antineoplastic Combined Chemotherapy Protocols
Cyclophosphamide
Doxorubicin
Humans
Japan
Lymphoma, T-Cell, Peripheral
Prednisone
Retrospective Studies
Vincristine

authors with profiles

Yuko Mishima